Answers are grounded in this paper and cite their sources.
In vitro evaluation shows zinc protoporphyrin inhibits heme oxygenase in spleen and other tissues, suggesting it may help prevent neonatal hyperbilirubinemia.
INTRODUCTION: Metalloporphyrins, competitive heme oxygenase (HO) inhibitors, may potentially be used as drugs for preventing neonatal hyperbilirubinemia. Metalloporphyrins that specifically target the inducible HO-1 without inhibiting the constitutive HO-2, are the most ideal. Zinc protoporphyrin (ZnPP) has the most promise. We have derived a plant-based ZnPP (ZnPP-Plant) and evaluated its inhibitory potency and selectivity for the HO-1 isozyme. METHODS: 11-µM ZnPP-Plant or technical grade ZnPP (ZnPP-TG) added to reaction vials with heme, NADPH, and adult mouse spleen, brain, and liver sonicates. Gas chromatography was used to measure total in vitro HO activity in sonicates. Percent inhibition of control HO activity was then compared. RESULTS: At a 11-µM concentration, ZnPP-Plant and ZnPP-TG inhibited HO activity in the liver (69.7±9.3 and 74.2±10.3%, respectively); spleen (46.8±8.7 and 65.8±17.9%, respectively); and brain (54.1±13.3%, and 38.1±13.9%, respectively). CONCLUSION: ZnPP-Plant has equal inhibitory potency as ZnPP-TG, and thus has potential use for treating neonatal hyperbilirubinemia.
No takes yet. Share an insight, caveat, or question.
Muchová et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: